Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OLX101A

            Therapeutic Area: Dermatology Product Name: OLX101A

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $37.2 million Upfront Cash: Undisclosed

            Deal Type: Financing December 01, 2020

            Details:

            Capital will fund construction of RNA synthesis GMP facility in San Diego to advance the company’s core pipeline, including OLX101A for hypertrophic scars, OLX301A for age-related macular degeneration and OLX301D for subretinal fibrosis.